Under physiological conditions, insulin stimulates the uptake of glucose into cardiac muscle, skeletal muscle, liver, adipose tissue and other metabolic tissues to main tain glucose homeostasis 1, 2 . Reduced insulin signalling and/or insulin resistance, together with the associated diminution in glucose transport, promotes a compen satory increase in pancreatic production of insulin that results in hyperinsulinaemia 3, 4 . Insulin resistance and hyperinsulinaemia are often associated with the cardio renal metabolic syndrome, which comprises a constella tion of cardiac, renal and metabolic disorders contributing to the early stages of cardiovascular and renal disease [1] [2] [3] [4] [5] . The first clinical description of cardiomyopathy associ ated T2DM was published in 1972 and involved four patients with diabetes mellitus who had died of heart failure 6 . Anatomical dissection of their hearts revealed a form of cardiomyopathy characterized by abnormal myo cardial structure but no evidence of coronary artery dis ease, hypertension or other known precipitating factors for heart failure 1, 2, 7, 8 . The term 'diabetic cardiomyo pathy' was proposed to distinguish the pathophysiological changes observed among these patients from patients with other forms of cardiomyopathy 2, 9 . Diabetic cardio myopathy was defined as left ventricular dysfunction that occurs among patients with diabetes mellitus independ ent of recognized risk factors, such as coronary artery disease or hypertension 10 . Minimal criteria for diagnosis of diabetic cardiomyopathy include left ventricular dia stolic dysfunction and/or reduced left ventricular ejec tion fraction, left ventricular hypertrophy and interstitial fibrosis 1, 4 . Diabetic cardiomyopathy seems to progress through an initial subclinical period characterized by subtle structural and functional abnormalities (for exam ple, diastolic relaxation) through to severe diastolic heart failure with normal ejection fraction followed by systolic dysfunction accompanied by heart failure with reduced ejection fraction 7, 10 . Research into the pathophysiology underpinning the progression of diabetic cardiomyopathy to heart failure has demonstrated the importance of systemic insulin resistance, impaired cardiac insulin signalling, mitochon drial dysfunction, endoplasmic reticulum stress, impaired calcium handling, abnormal coronary microcirculation, inappropriate neurohumoral activation and maladaptive immune responses 3, 10 . However, the precise role of insu lin resistance and hyperinsulinaemia in the patho genesis of diabetic cardiomyopathy remains to be elucidated. Understanding the molecular and metabolic pathways 
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Predictive factors for heart failure Type 2 diabetes mellitus The prevalence of heart failure is estimated to be 22% among patients with type 2 diabetes mellitus (T2DM) 11 . These two conditions tend to coexist and the impact of each disorder on the other results in bidirectional effects in terms of causation and outcome 12, 13 . The Framingham Heart Study reported that 19% of patients with heart failure have T2DM and that the risk of heart failure increases by twofold to eightfold in the presence of T2DM 7, 12, 14 . Furthermore, a 1% increase in the levels of HbA 1c is associated with an 8% increase in the risk of heart failure, independent of blood pressure, BMI, age and the presence of coronary artery disease, which suggests that the risk of heart failure is modulated by factors unique to T2DM, such as insulin resistance and hyperglycaemia 7, 12, 14 . Conversely, a 1% reduction of HbA 1c levels is associated with a 16% reduced risk of developing heart failure and worsening outcomes 12 . Such a bidirec tional interaction has, therefore, provided evidence to support the existence of diabetic cardiomyopathy as a unique clinical entity and suggests that the presence of diabetes mellitus might independently increase the risk of developing heart failure.
Insulin signalling
Cellular insulin signalling occurs through two key path ways (FIG. 1) . The first pathway involves insulin receptor substrate 1 (IRS1), which acts upstream of the phos phatidylinositol 3kinase (PI3K)-protein kinase B (also known as AKT) signal transduction pathway to elicit predominantly metabolic responses. For example, PI3K is positioned to phosphorylate the lipid phosphatidylin ositol 4,5bisphosphate and induces the conversion of phosphatidylinositol 4,5bisphosphate to phosphatidyl in ositol 3,4,5trisphosphate, which initiates a kinase cas cade and further activates the AKT signalling pathway.
Activation of AKT increases the glucose uptake in the heart by allowing the translocation of GLUT4 to the cell membrane of cardiac cells. PI3K-AKT can also activate endothelial nitric oxide synthase 15 . The resultant increase in bioavailable nitric oxide mediates coronary vasodila tion, myocardial substrate flexibility and energy homeo stasis 16 . The second pathway involves signal transduction via mitogenactivated protein kinase (MAPK) 15 , which contributes to growth and remodelling responses and the resultant myocardial hypertrophy, cardiac fibrosis, impaired myocardial-endothelial signalling and death of myocardial and endothelial cells 17 . Thus, insulin signalling in the heart constitutes a highly complex network with multiple feedback loops and crosstalk (FIG. 1) .
Insulinresistant states exhibit an imbalance in the metabolic and growth effects of insulin signalling, with the actions of the MAPK pathway predominating. A major converging point in insulin signal transduction seems to underlie this imbalance; namely, increased phospho rylation of serine of the critical insulin signalling factor IRS1 leads to impaired PI3K engagement and stimulation of AKT [15] [16] [17] . As shown in FIG. 1 , following activation by changes in oxidation-reduction state or nutritionrelated factors, several serine kinases have the ability to attenuate engagement of IRS and PI3K via phosphoryl ation of ser ine residues on IRS1 and/or IRS2 (REF. 18 ). Overnutrition and excess renin-angiotensin-aldosterone system activa tion are increasingly recognized as having an interactive action on the stimulation of mechanistic target of rapa mycin (mTOR)-S6 kinase 1 (S6K1) signalling, which, in turn, attenuates insulin metabolic signalling such as IRS1 and IRS2 and PI3K-AKT in cardiovascular tis sues. In the past few years, work from our laboratory indicates that angiotensin II activates S6K1 in heart and vascular tissue and leads to diminished insulin metabolic signalling and biological consequences, such as impaired NOmediated vascular relaxation and impaired myocar dial glucose utilization and diastolic relaxation [16] [17] [18] . These findings support the notion that cardiac insulin resist ance is a metabolic and functional disorder that is often associated with obesity and the development of diabetic cardiomyopathy (FIG. 1) .
Pathophysiological mechanisms
Several factors have been proposed to explain the patho genesis of diabetic cardiomyopathy. These factors include cardiac metabolic disturbances, subcellular signalling abnormalities, autonomic dysfunction, activation of the renin-angiotensin-aldosterone system, inflammation, oxidative stress and a maladaptive immune response. Collect ively, they contribute to the functional impairments associated with diabetic cardiomyopathy 13, 19 (FIG. 2) .
Systemic metabolic disorders
Alterations in substrate metabolism. Impaired myocar dial substrate and energy metabolism has emerged as an important contributor to the development of diabetic cardiomyopathy and subsequent heart failure 13, 20 . Under physiological conditions, the heart can use both fatty acids and glucose as energy substrates, thus provid ing metabolic flexibility. Uptake of fatty acids is mediated
Key points
• Reported rises in the prevalence of diabetic cardiomyopathy among developed nations have occurred in parallel with increased rates of obesity, insulin resistance and hyperinsulinaemia • Insulin resistance and/or hyperinsulinaemia seem to underpin the development of diabetic cardiomyopathy, which is initially characterized by diastolic dysfunction in the absence of coronary artery disease and hypertension • Pathophysiological mechanisms include impaired insulin signalling, cardiac mitochondrial dysfunction, endoplasmic reticulum stress, impaired autophagy, impaired myocardial calcium handling, abnormal coronary microcirculation, inappropriate neurohumoral activation and maladaptive immune responses • Insulin resistance, or hyperinsulinaemia, independently predisposes to the development of diabetic cardiomyopathy and targeting insulin resistance or hyperinsulinaemia could be a potential therapeutic strategy to prevent the development of diabetic cardiomyopathy by the cluster of differentiation 36 (CD36) and fatty acid translocase (FAT), whereas glucose intake occurs through insulinstimulated glucose transport mediated by glucose transporter 4 (GLUT4) 13, 15, 21 (FIG. 3) . Nutrients increase plasma levels of insulin and myocardial insulin signalling, which facilitates translocation of GLUT4 and CD36 to the myocyte sarcolemma to supply myocardial energy sub strates 13 . By contrast, in states of insulin resistance and/or T2DM, CD36 becomes preferentially localized to the sarcolemma, whereas GLUT4 is internalized and returns to its intracellular location 22, 23 (FIG. 3) .
The reciprocal positioning of GLUT4 and CD36 influ ences the development of cardiac metabolic abnormali ties characterized by metabolic inflexability 22 . Thus, the reduced glucose uptake as a result of systemic and car diac insulin resistance facilitates a substrate shift toward increased free fatty acid oxidation in diabetes mellitus, resulting in reduced cardiac efficiency 24, 25 . Excessive accumulation of fatty acids in cardiac tissue and the asso ciated lipotoxicity impairs insulin signalling and reduces normal physiological autophagy, which leads to mor phological and structural alterations, as well as impaired myocardial performance 25 . These abnormalities increase myocardial oxygen use and can reduce the efficiency of the function of muscle fibres in response to electrical stimuli (electrical-mechanical coupling) 10, 26 .
During the advanced stage of diabetic cardiomyo pathy, signal transduction molecules involved in regulating βoxidation of fatty acids (for example, per oxisome proliferator activator receptorα (PPARα) and peroxisome proliferatoractivated receptor gamma coactivator 1α (PGC1α)) are also decreased, thereby further dampening the metabolic efficiency of the myo cardium 19, 27 (FIG. 3) . Therefore, the metabolic switch from glucose metabolism to fatty acid βoxidation in states of cardiac insulin resistance decreases functional efficiency of the cardiac tissue and thereby increases metabolic stress to the failing heart 19 .
Advanced glycation end products. Decreased glucose use and increased gluconeogenesis are both associ ated with the development of diabetic cardiomyopathy. Chronic hyperglycaemia impairs cardiac structure and function through generation of reactive oxygen species (ROS), which leads to DNA damage and inhibition of glyceraldehyde 3phosphate dehydrogenase (G3PDH) activity and the formation of advanced glycation end products 28 (FIG. 3) . This diverse group of compounds is formed by nonenzymatic reactions between reducing sugars and the free amino groups of proteins, lipids and nucleic acids. Advanced glycation end products could have a pivotal role in the development and progression of diabetic cardiomyopathy by stimulating collagen expression and accumulation and by promoting colla gen crosslinking, which leads to increased myocardial fibrosis and reduced compliance 20 .
Hyperlipidaemia. The combination of increased lipid synthesis in hepatocytes and increased lipolysis in adipo cytes results in raised levels of circulating free fatty acids and triglycerides in patients with insulin resistance and/or T2DM 28 . Lipid accumulation (lipotoxicity) can directly impede myocyte metabolism and contractility; it can also promote cardiomyocyte apoptosis via increased production of ROS and endoplasmic reticulum stress 29 .
Subcellular component abnormalities
Metabolic abnormalities involving mitochondria dys function, endoplasmic reticulum stress and impaired calcium handling contribute to the pathogenesis of diabetic cardiomyopathy 13, 25, 30 . In conditions of excessive intake of carbohydrates and fat and associated insulin resistance, nutrient overflow into cells prompts electrons to transfer to oxygen with out ATP production and also favours a state of increased ROS, which potentially leads to oxidative damage within mitochondria 31 . Therefore, in the presence of ROS gen erated from mitochondria, proteins, DNA and lipid membrane components are damaged and accumulation of ROSmediated fibrosis promotes diastolic dysfunction that can progress to heart failure.
Excessive production of ROS also exerts deleterious effects on the endoplasmic reticulum by impairing pro tein folding and other posttranslational modifications that occur in the rough endoplasmic reticulum 32 . Stress to the endoplasmic reticulum results in an adaptive response, termed the unfolded protein response, which results in increased proteasome degradation of incor rectly folded proteins 30 
. Conversely, endoplasmic reticulum stress also contributes to myocardial oxidative stress and the associated reduction in insulin signalling by activation of serine kinases dependent on the cellular oxidation-reduction state 33, 34 
Oxidative stress and endoplasmic reticulum stress can induce abnormalities of calcium handling, which subsequently lead to diabetic cardiomyopathy and dias tolic dysfunction. Longchain acylcarnitines, ROS and abnormal membrane lipid content in the mitochon drial membrane, such as cardiolipin, can alter calcium handling by affecting various transporter proteins, which leads to impaired intracellular calcium uptake and delayed diastolic relaxation 10, 26, 35 . The interaction of ROS, endoplasmic reticulum stress and abnormal calcium handling promote subcellular component dys function and ultimately cause apoptosis, necrosis and autophagy 2, 36 . Apoptosis is induced by pro apoptotic proteins through permeabilisation of the outer mito chondrial membrane in response to increased pro duction of ROS and mitochondria dysfunction 37, 38 . By contrast, necrosis occurs in response to opening of the mitochondrial permeability transition pore, which causes rapid influx of solutes and water into the mitochondrial matrix, collapse of the proton gradient and disruption of ATP synthesis 39 . Mitochondria are also closely associated with the endoplasmic reticu lum and Ca 2+ release from this organelle via inositol Figure 2 | The development and progression of diabetic cardiomyopathy. Insulin resistance and hyperinsulinaemia increase systemic metabolic disorders, activate the SNS, activate RAAS, prompt oxidative stress, mitochondrial dysfunction and endoplasmic reticulum stress and impair calcium homeostasis. These effects result in cardiac fibrosis, hypertrophy, cardiomyocyte death, dysfunction of the coronary microcirculation and eventually heart failure. Furthermore, these pathophysiological changes in cardiomyocytes underlie the risk factors for insulin resistance and hyperinsulinaemia, which can result in a potentially vicious cycle. [Ca 2+ ] i , Ca 2+ influx; RAAS, renin-angiotensin-aldosterone system; SNS, sympathetic nervous system. triphosphate; mitochondria can also promote apoptosis. Excess uptake of Ca 2+ by the mitochondria leads to Ca 2+ overload and opening of the mitochondrial permeability transition pore 40 . Dysfunction of autophagy can contribute to the development of obesityrelated cardiac dysfunction in individuals with insulin resistance or cardiorenal meta bolic syndrome through mTORdependent signalling 41 . Overfeeding and obesity activate this pathway, which in turn inhibits activation of serine/threonineprotein kinase ULK1 via phosphorylation. This phosphorylation event disrupts the interaction between serine/threonineprotein kinase ULK1 and adenosine monophosphateactivated protein kinase (AMPK), thereby blocking autophagy and promoting development of cardiorenal metabolic syn drome 5, [41] [42] [43] . Impairment of autophagy can be attributed to defects in autophagosome and lysosome fusion and results in both diastolic and systolic cardiac dysfunction as diabetic cardiomyopathy increases in severity 41, 44 .
Impaired coronary microcirculation
Impaired coronary microcirculation is frequently observed in patients with insulin resistance, T2DM and diabetic cardiomyopathy 32, 36, 45 . This impairment is driven by reduced levels of bioavailable nitric oxide 46 . In coronary vascular smooth muscle cells, nitric oxide activates both guanylyl cyclase (the enzyme responsi ble for producing cyclic GMP) and kinases required for coron ary relaxation 47 . Under conditions of reduced insu lin sensitivity, both reduced nitric oxide production and increased nitric oxide degradation occur. Nitric oxide usually induces vascular relaxation by reduction of the phosphorylated state of myosin light chain phosphatase and myosin light chain kinase sensitization or activation. Thus, both increases in vascular smooth muscle cell lev els of intracellular Ca 2+ and Ca 2+ sensitization increase the ambient state of coronary constriction in states of diminished insulin signalling.
Insulin resistance and hyperinsulinaemia are associ ated with stiffness of both the large and small blood vessels 48 . The increased plasma levels of insulin that are characteristic of hyperinsulinaemia enhance the differentiation of vascular smooth muscle cells to an osteoblastlike phenotype, which could contribute to the observed increase in vascular stiffness 49 . Raised insulin levels might also promote vascular stiffness by increasing alkaline phosphatase activity, osteocalcin expression and the formation of mineralized nodules in vascular smooth muscle cells through increased lev els of receptor activator of nuclear factor κB 50 . Thus, impaired endothelial cell and vascular smooth muscle cell function are associated with an increased risk of developing coronary artery disease in association with diabetic cardiomyopathy.
Inappropriate neurohumoral activation
A relationship exists between nervous system activa tion states and the development of diabetic cardiomy opathy 51 . Activation of the sympathetic nervous system increases β1adrenergic expression and signalling, which promotes myocyte hypertrophy, interstitial fibrosis and reduced contractile function accompanied by increased myocyte apoptosis 10, 26 . Activation of the parasympa thetic nervous system is reduced, muscarinic receptor density and composition are altered and acetylcho linesterase activity is decreased in heart failure 52 . Either direct or indirect vagus nerve stimulation might have direct beneficial effects on cardiac remodelling and clinical outcomes 52 . Increased activation of the renin-angiotensinaldosterone system in states of insulin resistance or hyperinsulinaemia has an important role in the patho genesis of various cardiovascular diseases, including coronary artery disease and heart failure 5, 28, 53 . Moreover, enhanced activation of angiotensin I and mineralo corticoid receptor signalling might promote insulin resistance through activation of the mTOR-S6K1 signal transduction pathway 5, 28, 53 (FIG. 1) . S6K1 is activated by angiotensin II type 1 receptor (AT1R) and mineralo corticoid receptor signalling in cardiovascular tissue leading to diminished insulin signalling and down stream biological consequences, such as impaired vas cular and cardiac relaxation mediated by nitric oxide 16, 17 . Both AT1R and mineralocorticoid receptor signalling increase vascular oxidative stress, mainly through stim ulation of NADPH oxidase activity 5, 28, 53 . Aldosterone signalling via the mineralocorticoid receptor also increases the expression and activity of the epithelial sodium channel in the vascular cell membrane and activates serum/glucocorticoidregulated kinase 1 to reduce production of nitric oxide, promote vascular and Under T2DM conditions, the expression of cardiac PPARα and PGC-1α is increased, which enhances the transcription of proteins that control free fatty acid uptake and oxidation. As glucose is a more efficient substrate than free fatty acids, a cardiac metabolic switch from glucose metabolism to free fatty acid oxidation decreases cardiac efficiency. This switch results in further metabolic disorders to cardiac dysfunction. CD36, cluster of differentiation 36; GLUT4, glucose transporter 4; T2DM, type 2 diabetes mellitus; PPARα; peroxisome proliferator activator receptor-α; PGC-1α, peroxisome proliferator-activated receptor gamma co-activator 1α; ROS, reactive oxygen species.
cardiac stiffness and impair cardiac relaxation 54 . Both AT1R and mineralocorticoid receptor signalling in the myocardium enhance activation of growth signalling, as well as the profibrotic transforming growth factor β1 (TGFβ1)-SMAD pathway to regulate morphogenesis, proliferation, cellular differentiation, gene expression and tissue remodelling 10, 17 . Thus, the interaction of insulin resistance with renin-angiotensin-aldosterone system activation contribute to the cardiac fibrosis and diastolic dysfunction that characterize the early stages of diabetic cardiomyopathy (FIG. 2) .
Maladaptive immune responses
Diabetic cardiomyopathy can be promoted by alter ations in the innate and adaptive immune systems 55, 56 . Activation of proinflammatory T helper cells and macro phage polarization to classic (M1) or alternative (M2) phenotypes often occurs in states of obesity or insulin resistance 17 . In addition, chronic overfeeding results in immune responses that contribute to low grade inflammation within the white adipose tissue 21 . Increased levels of free fatty acid storage and visceral adipose tissue promotes systemic and cardiovascular inflammatory cytokine expression. Macrophage M1 polarization is a proinflammatory response and M2 polarization is an antiinflammatory response in obesity and insulinresistant states 17, 57 . The M1 macro phages secrete inflammatory cytokines that cause reduced systemic and cardiac insulin signalling and pro mote the development of diabetic cardiomyopathy 17 . By contrast, M2 macrophages secrete IL10 and macrophage mannose receptor 1, which reduce the development of cardiomyocyte hypertrophy and cardiac fibrosis 17, 58 . Another population of immune cells (T helper lym phocytes) have been identified in patients with diabetic cardiomyopathy 59 . A higher CD8 + :CD4 + Tcell ratio is found in visceral adipose tissue of mice fed a highfat diet than in lean mice 60, 61 . Dietinduced insulin resist ance also leads to a dramatic increase in type 1 T helper (T H 1)polarized cells, whereas the type 2 T helper (T H 2) polarized fraction is reduced by ~50% 60 . These cells can be subtyped according to their cytokine expression profile following activation 61 . Increased secretion of proinflammatory cytokines, chemokines and growth fac tors by T helper lymphocytes leads to increased cardiac fibrosis and impaired diastolic relaxation 62 . However, regulatory T cells usually attenuate the proinflamma tory effects of T helper cells in the myocardium 63 . The mechanisms by which regulatory T cells protect against inflammation are thought to be mediated, at least in part, by directing celltocell interactions, as well as through secretion of soluble antiinflammatory cytokines, such as IL10 and TGFβ 64 . Thus, systemic and local adaptive immune responses and inflammation might result in changes in myocardial structure and metabolism that can progress to diastolic dysfunction and eventually heart failure.
Progression of diabetic cardiomyopathy
Left ventricular filling of the normal healthy heart at rest is largely passive and is mostly accomplished (~90% of filling) before the next contraction of the left atrium. In healthy individuals, only ~10% of ventricular fill ing occurs as a result of left atrial contraction (active filling phase) 65, 66 . Abnormalities in diastolic filling, like those that occur in association with obesity and T2DM, are characterized by metabolic and structural disturbances that over time lead to a decrease in ven tricular wall compliance and impairment in the pas sive filling phase of the left ventricle. During disease progression this can be compensated for, in part, by a greater contribution of the left atrium to active filling. Noninvasive detection of diastolic dysfunction in the clinical setting is routinely accomplished with conven tional echocardiography 28, 67 . The progression of diabetic cardiomyopathy is characterized by three distinct stages with different pathophysiological features and clinical outcomes (TABLE 1) .
Early stage
In the early stage of diabetic cardiomyopathy, metabolic disturbances, such as insulin resistance and hypergly caemia, are not accompanied by substantial changes in myocardial structure and systolic function 2, 10 . However, impaired myocardial relaxation can be detected by echocardiography and MRI. Studies in rodents indicate that excessive dietary intake of refined carbohydrates and fats (the socalled Western diet) leads to systemic insulin resistance, impaired insulin signal ling and diastolic relaxation without any evidence of systolic dysfunction 17, 68, 69 . This impaired diastolic relax ation was characterized as slow initial and peak filling rates as assessed by cine MRI 17, 68, 69 . These impairments were also evidenced by abnormal echocardiographic diastolic parameters, including impaired septal annular wall motion, abnormal myocardial performance index and a long period of isovolumic relaxation 28, 68 . Diabetic cardiomyopathy is initially characterized by increased cardiac stiffness and impaired relaxation with a reduction in early diastolic filling and an increase in atrial filling 10 (TABLE 1) . Impaired insulin signalling also causes a decrease in myocardial bloodflow reserve that can be detected by various imaging techniques 70 .
Box 1 | Endoplasmic reticulum stress in diabetic cardiomyopathy
Endoplasmic reticulum is an important post-translational modification site and is responsible for proper protein folding in eukaryotic cells. The presence of reactive oxygen species (ROS) can cause cellular damage through protein oxidation, improper protein folding, DNA damage and intrinsic action on mitochondria, as well as cell toxicity. Endoplasmic reticulum stress results in the unfolded protein response, which causes increased proteasomal degradation of improperly folded proteins. Endoplasmic reticulum stress also contributes to cardiac lipotoxicity by increasing lipogenesis through increased activation of the sterol regulatory element binding protein.
Endoplasmic reticulum stress prompts membrane instability to release Ca 2+ from sarcoplasmic reticulum stores into the cytosol and reduces activity of the sarcoplasmic reticulum calcium pump, which is responsible for Ca 2+ sequestration during cardiomyocyte diastolic relaxation. The interaction of ROS, endoplasmic reticulum stress and abnormal calcium handing leads to the lengthened diastolic relaxation time seen in initial diastolic dysfunction and causes cardiomyocyte apoptosis and cell death as a result of the mitochondrial permeability transition pore response in the later stages of diabetic cardiomyopathy.
Advanced stage
In the advanced stage of diabetic cardiomyopathy, a number of changes at the cellular level (impaired auto phagy of cells that have undergone death by apopto sis and/or necrosis, oxidative stress and maladaptive immune response) increase cardiac fibrosis, which results in substantial changes in diastolic function (initially) and systolic function (later in the process) 26 .
Late stage
In the late stage of diabetic cardiomyopathy, changes in metabolism, neurohumoral activation and development of myocardial fibrosis further impair coronary micro circulation, diastolic function and systolic function 2, 71 (TABLE 1). Numerous studies have reported that impaired myocardial insulin signalling leads to reduced activa tion of endothelial nitric oxide synthase and reduced levels of bioavailable nitric oxide 10, 17, 68, 69, 72, 73 . The reduc tion in nitric oxide is further augmented by elevations in oxidative stress, which increase the destruction of this mol ecule. Increases in ROS and inflammation, together with decreases in bioavailable nitric oxide, promote inter stitial collagen deposition and crosslinking, which is associated with interstitial fibrosis and impaired myocar dial relaxation. For example, activation of the profibrotic TGFβ1-SMAD signalling pathway increases myocar dial collagen and fibronectin content and interstitial fibrosis in concert with impaired insulin signalling 17, 28 . Structural abnormalities associated with diabetic cardio myopathy include cardiomyocyte necrosis, progressive abolition of muscular fibrils, collagen formation in con nective tissue, interstitial or/and perivascular fibrosis, hypertrophy, thickened and sclerotic small coronary ves sels, basement membrane thickening, hyaline arteriolar sclerosis and capillary microaneurysms 23, 29 .
Sexual dimorphism
Nondiabetic premenopausal women have a lower inci dence of cardiovascular disease than agematched men; however, the incidence of complications of cardio vascular disease is increased among women with obesity or diabetes mellitus 74 . The Framingham Heart Study found sexrelated dif ferences in participants with worsening glucose intoler ance, including the fact that left ventricular mass and wall thickness were greater in women than in men 75 . The levels of aldosterone were also higher in women than in men, and were positively associated with markers of concentric remodelling, such as left ventricular wall thickness [74] [75] [76] . Feeding mice a Western diet for 8 weeks induced greater systemic and cardiac insulin resistance in female animals than in male animals 74 . Furthermore, female, but not male, mice went on to develop cardiac diastolic dysfunction in response to this dietary intevention 74 . The observed dimorphic effects might be explained, in part, by loss of the beneficial actions of oestrogen, which protects against cardiovascular disease 77 . Thus, women seem to be prone to the development of dia betic cardiomyopathy associated with insulin resistance and/or hyperinsulinaemia.
Prevention of diabetic cardiomyopathy Lifestyle interventions
Weight loss, regular physical activity and limitation of fat and total energy intake can positively modify metabolic abnormalities and improve systemic and tissue insulin resistance by increased postreceptor insulin signalling and insulinmediated glucose transport, which seems to be related to enhanced signal transduction at the level of IRS proteins and PI3K 8, 28 . Multifaceted lifestyle intervention, such as diet, exercise, nutrition education and lifestyle management, improved several risk factors associated with cardiovascular disease, including BMI and HbA 1c in patients with, or at risk of, T2DM 78 . For example, longterm caloric restriction in patients with obesity and/or T2DM decreased myocardial trigly ceride content and improved diastolic left ventricular dysfunction 79 . Following an exercise training program, an exercisebased lifestyle intervention prevented pro gression of diastolic left ventricular dysfunction 80 and raised left ventricular ejection fraction by 2-5% in both the patients with obesity and those with T2DM 81, 82 .
Metabolic modulators
Several drugs increase myocardial efficiency by promot ing glucose metabolism and decreasing metabolism of free fatty acids 14 . Perhexiline is an inhibitor of carnitine 0palmitoyltransferase 1 that increases maximal O 2 con sumption (VO 2 max), left ventricular ejection fraction, resting and peak stress myocardial function and skeletal muscle energetics 83 . In patients with chronic heart fail ure, a multicentre doubleblind randomized controlled trial showed that perhexiline improved left ventricular ejection fraction, resting and peak stress myocardial function, VO 2 max and skeletal muscle energetics. Despite these benefits, the use of the perhexiline is declining due to reports of hepatotoxicity and peripheral 84 . Trimetazidine is a competitive inhibitor of the terminal enzyme in βoxidation that might be used to potentially improve myocardial metabolic or substrate flexibility and cardiac function in the setting of diabetic cardiomyopathy 83 . Trimetazidine might affect myocardial substrate use by inhibiting oxidative phosphorylation and shifting energy production from free fatty acids to glucose oxidation 85 . This drug might also contribute to the preservation of intracellular levels of phosphocreatine and ATP, reduce calcium overload and free radicalinduced injury, inhibit cell apoptosis and improve endothelial function 85 . Resveratrol reduces blood levels of glucose and improves insulin sensitiv ity and cardiac function in patients with heart failure 86 . Although resveratrol is associated with improved gly caemia, triglyceride levels and heart rate, resveratrol is not associated with prevention of total mortality, cancer or cardiovascular events 87 . Ranolazine, a potent late Na + current inhibitor, might normalize altered cardiomyo cyte intracellular Ca 2+ concentration due to the close relationship between Na + and Ca 2+ handling by the Na + /Ca 2+ exchanger 88 . Ranolazine improves measures of haemodynamics but cardiac relaxation parameters did not improve 88 . A single treatment with ranolazine is probably not sufficient to affect cardiac structure and function 88 .
Targeting mitochondrial oxidative stress
Given the important role of oxidative stress in the devel opment of diabetic cardiomyopathy, targeting excess myocardial production of ROS with novel antioxidants might offer a promising approach for preventing dia betic cardiomyopathy. For example, the Szeto-Schiller peptide SS31 is a positively charged freeradical scav enger that can accumulate to high levels in the mito chondria and prevent cardiac hypertrophy, fibrosis and diastolic dysfunction [89] [90] [91] . SS31 prevents cardiolipin from converting cytochrome c into a peroxidase while protecting cardiolipin electron carrying function by interacting with cardiolipin 92 . SS31 also protects the structure of mitochondrial cristae and promotes oxi dative phosphorylation 92 . Thus, SS31 represents a new class of compounds that can recharge the cellu lar powerhouse and restore bioenergetics. Coenzyme Q 10 has also been reported to improve cardiac function in patients with diabetes mellitus who have heart fail ure 90, 91, 93 . A randomized controlled trial showed that longterm coenzyme Q 10 treatment in patients with chronic heart failure is safe, improves symptoms and reduces cardiovascular death by 43% and allcause mortality by 42% 94 .
Antidiabetic medications
Thiazolidinediones are insulin sensitizers that improve myocardial glucose uptake and contractile dysfunc tion by activation of PPARγ 95, 96 . However, thiazoli dinedione therapy can induce chronic symptoms that resemble heart failure by increasing sodium and water reabsorption in kidney collecting tubules, as well as vas cular permeability, which leads to systemic oedema 97 . Metformin has been reported to improve the clinical outcome and reduce mortality in spite of the increased risk of lactic acidosis in overweight patients with dia betes mellitus and heart failure 98 . This drug stimulates GLUT4 translocation and glucose uptake in cardiac muscle and in insulinresistant cardiomyocytes by activation of AMPK 98, 99 . Glucagonlike peptide 1 stim ulates insulin secretion, improves vasodilation medi ated by nitric oxide and promotes glucose use in the myocardium 89, 95, 100 . Dipeptidyl peptidase 4 inhibitors can prevent cardiac hypertrophy and cardiac dias tolic dysfunction by inhibition of oxidative stress and fibrosis in mouse models of obesity and insulin resist ance 69 . However, no clinical studies have yet docu mented a beneficial effect of glucagonlike peptide 1 or dipeptidyl peptidase 4 agonists on cardiac function or clinical outcomes. Empagliflozin, an inhibitor of sodium glucose cotransporter 2, is a new antihyperglycaemic agent and has been reported to reduce HbA 1c levels in patients with T2DM by controlling blood pressure, weight, visceral adiposity, hyperinsulinaemia, arterial stiffness, albuminuria, circulating uric acid levels and oxidative stress 101 . In an EMPAREG OUTCOME trial involving patients with T2DM, empagliflozin with standard therapy (such as a healthy diet plan, exercise and anti diabetic therapy) resulted in a lower rate of the primary composite cardiovascular outcome and of death than adding placebo to standard therapy, but an increased rate of genital infection was observed 102 .
Other therapies
Blockade of βadrenergic responses, the reninangiotensin-aldosterone system and xanthine dehy drogenase/oxidase can attenuate oxidative stress, inflammation and insulin resistance to improve cardiac function 28 . Cellbased therapy and genetic correction of abnormalities are also potential strategies to pre vent the development of diabetic cardiomyopathy or to treat the early stage of this condition 103, 104 . For exam ple, gene delivery of nerve growth factor preserves left ventricular systolic and diastolic function, microvessel density and cardiac perfusion 105 . Systemic administra tion of the Pim-1 gene improves left ventricular diastolic function (E/A ratio) and prevents cardiac fibrosis, apop tosis and development of heart failure 106 . Furthermore, six miRNAs (miR34b, miR34c, miR199b, miR210, miR223 and miR650) might be involved in the patho genesis of the failing myocardium in patients with diabetes mellitus 107 . Thus, miRNAs have become an active area of investigation to determine their potential contribution to heart disease in patients with T2DM. Therapies based on miRNAs might be useful in patients with diabetes mellitus who have cardiac pathology 107 . These studies have led to enthusiasm and anticipation for the development of further genebased therapies. Pharmaceutical companies have invested in gene based therapies to target heart failure in T2DM. Further understanding of the mechanisms responsible for the onset of the functional and structural complications in the diabetic heart will undoubtedly aid the develop ment of more precise therapeutics for the treatment of diabetic cardiomyopathy.
Conclusions
We integrated abnormalities in cardiomyocytes, which are characterized by abnormalities of metabolism, sub strate flexibility, inflammation, oxidative stress and endoplasmic reticulum stress, with resulting tissue fibro sis and reduced vascular and myocardial compliance, to understand the pathogenesis of diabetic cardiomyopathy and heart failure. Insulin resistance and hyperinsulinae mia are independently associated with the development of diabetic cardiomyopathy and cardiac diastolic dys function. Patients with obesity, insulin resistance and hyperinsulinaemia are at high risk of developing diabetic cardiomyopathy and heart failure. Further research is needed to understand the precise mechanisms involved in the development and course of diabetic cardiomyo pathy to facilitate the discovery of clinically effective targets for preventing this condition and its progression to heart failure.
